BaCKgROunD anD OBjECtIVES: in recent years, there has been an increasing role for stem cell transplantation in the management of retinoblastoma. the aim of this study was to systematically review the role high-dose chemotherapy followed by stem cell transplantation in the treatment of patients with metastatic or relapsed, trilateral or bilateral advanced retinoblastoma, and in patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension. DESIgn: systematic literature review. mEthODS: We performed an extensive Pubmed database search on 25 february 2012 for studies describing the use of high-dose chemotherapy followed by stem cell transplantation in the management of patients with retinoblastoma. RESuLtS: We located 15 studies that met the inclusion criteria and that included 101 patients. following treatment for metastatic and relapsed disease, 44 of 77 patients (57.1%) were alive with no evidence of disease at the time of follow-up. however, a higher rate of local relapse developed in patients with Cns metastases (73.1%), which dropped to 47.1% in patients who received thiotepa. in patients with trilateral or bilateral advanced retinoblastoma, 5 of 7 (71.4%) with reported outcome data were alive with no evidence of disease at the time of followup. in patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension, 6 of 7 patients (85.7%) were alive with no evidence of disease at the time of follow-up. COnCLuSIOnS: Durable tumor control is possible in patients with non-Cns metastases, trilateral or bilateral advanced retinoblastoma, and in patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension. Patients with Cns metastases require thiotepa to improve tumor control. plantation in the treatment of patients with metastatic or relapsed, trilateral or bilateral advanced retinoblastoma, and for patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension.
R etinoblastoma is the most common intraocular malignancy in childhood. 1 In developed countries, most patients present with confined, intraocular disease. Secondary to late presentation, advanced retinoblastoma (locally advanced and metastatic disease) is more common in developing countries and is associated with exceedingly poor prognosis. In these cases, response to conventional therapies (enucleation, external-beam radiotherapy, and chemotherapy) has been poor. Several groups have proposed the use of high-dose chemotherapy in these patients; however, only a limited number of studies have addressed the role of high-dose chemotherapy followed by stem cell transHigh-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review Imad Jaradat, a Rasmi Mubiden, a Ahmed Salem, a Fawzi Abdel-Rahman, b Iyad Al-Ahmad, b Abdelatief Almousa a the date of publication; however, this search was limited to papers in English. Reports describing the utilization of high-dose chemotherapy followed by stem cell transplantation in the management of patients with retinoblastoma were considered. Studies addressing the role of chemotherapy were excluded if no direct mention was made to the rescue of the bone marrow with subsequent stem cell transplantation. Furthermore, reference lists of included studies were hand-searched to identify relevant missing publications. Articles were assessed and selected for inclusion by all authors. Full text articles of eligible abstracts were reviewed. Only original studies were included. Data pertaining to date of publication, study design and period, country of origin, number of patients, indication for treatment, chemotherapy regimen, therapeutic outcomes and associated toxicity were extracted using a predefined datasheet. Adequate high-dose chemotherapy regimens were defined as those consisting of a platinum agent and an alkylating compound in addition to etoposide. 17 Due to its excellent CNS penetration, the impact of thiotepa on the incidence of CNS relapse in patients with metastatic retinoblastoma was evaluated.
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RESuLtS
The preliminary search yielded 53 abstracts. Three nonEnglish publications were excluded. Of the remaining 50 studies, 20 were excluded following the first screen of the title and abstract. Thirty full-text articles were retrieved for detailed evaluation of which 17 were ineligible (did not address the use of high-dose chemotherapy followed by stem cell transplantation (n=16) or reported overlapping patient populations (n=1). Additionally, 2 papers were identified from the reference lists of included reports. Overall, 15 studies, which include 101 patients, met the inclusion criteria and formed the basis of this systematic review (Figure 1 ). The analysis involved 77 patients with metastatic or relapsed retinoblastoma (13 articles; Table 1 ), 17 patients with trilateral or bilateral advanced retinoblastoma (3 articles; Table 2 ), and 7 patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension (2 articles; Table 3 ). Since most studies were retrospective in nature and reported on a heterogenous group of patients, strict inclusion and exclusion criteria could not be assessed.
Secondary to the poor overall prognosis of retinoblastoma cases with CNS metastases, we opted to classify metastatic retinoblastoma patients into those presenting with or without CNS disease. Of a total of 77 included patients, 26 and 43 patients presented with CNS and non-CNS metastases, respectively, while only 8 patients in this group harbored isolated orbital relapse. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Of 69 patients who received high-dose chemotherapy, 53 patients (76.8%) received an adequate chemotherapy combination. Treatment-associated morbidity data were available in 7 reports and consisted mainly of grade IV hematological and gastrointestinal toxicity. 3, 4, 7, 8, [11] [12] [13] One patient died secondary to this intensive chemotherapy protocol. 6 Overall, 44 patients (57.1%) were alive with no evidence of disease at the time of follow-up. Treatment outcome was not as good in patients presenting with CNS metastases where 19 of 26 patients (73.1%) eventually developed CNS relapse, probably secondary to the use of inappropriate chemotherapeutic regimens (associated with poor CNS penetration); only 8 of 17 (47.1%) patients who received thiotepa subsequently developed CNS relapse. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Eight patients had trilateral retinoblastoma while 9 harbored bilateral advanced disease.
10,15,16 Lee et al 16 reported neutropenic fever and hepatic veno-occlusive disease in 9 of 9 and 2 of 9 patients, respectively. In addition, Dunkel and colleagues 10 reported on 1 patient who died due to septicemia and multi-organ system failure secondary to chemotherapy. Overall, 5 of the 7 patients (71.4%) with reported outcome data were alive with no evidence of disease at the time of follow-up.
10,15
Seven patients with tumors at the surgical margin of the optic nerve and/or extrascleral extension were treated with high-dose chemotherapy followed by stem cell transplantation. 2, 4 Kremens et al 4 reported grade IV gastrointestinal treatment-related toxicity; however, no treatment-related mortality was reported. Overall, 6 of 7 patients (85.7%) were alive with no evidence of disease at the time of follow-up.
2,4
DISCuSSIOn
This study represents the first detailed systematic review addressing the role of high-dose chemotherapy followed by stem cell transplantation in retinoblastoma. Unfortunately, most of the included studies were small retrospective case series (n=9) [2] [3] [4] 6, 8, 10, 12, 13, 16 or single case reports (n=5). 5, 7, 9, 11, 14 There was only one prospective report that addressed the use of stem cell transplant in pediatric malignancies in general and included 1 patient with trilateral retinoblastoma. 15 In addition, most of the reviewed reports originated from developed countries (n=12). 2, [4] [5] [6] [7] [8] [11] [12] [13] [14] [15] [16] According to our review, the use of high-dose chemotherapy followed by stem cell transplantation in retinoblastoma patients was first proposed by Matsubara et al 8 2 and trilateral retinoblastoma (first patient treated in 1997).
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The treatment protocol in the majority of included studies consisted of induction poly-chemotherapy (with the aim of achieving partial or complete tumor response) followed by high-dose chemotherapy and autologous stem cell transplantation. Only one case report narrated the performance of allogeneic stem cell transplantation using an identical HLA-matched sibling. 5 In conjunction with high-dose chemotherapy, externalbeam irradiation (for bulky, metastatic sites) has been reported 7 studies 2,3,6,8,10,12,13 while intra-thecal chemotherapy and radio-immunotherapy were reported in 4 studies. 4, 5, 8, 10 On the other hand, prophylactic cranial irradiation was less commonly prescribed. However, due to the non-randomized nature of the included studies and the variability of treatment protocols among patients in each study, we cannot accurately account for the impact of individual treatments on the outcome of these patients.
Thirteen studies addressed the role of high-dose chemotherapy followed by stem cell transplantation in patients with metastatic and relapsed retinoblastoma.
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Although metastatic retinoblastoma is more common in developing countries (secondary to late patient presentation/ diagnosis and lack of adequate healthcare facilities), only 3 reports originated from developing countries (including a case series jointly reported with a US institution).
3,9,10 Possible explanations for the lack of relevant publications from developing counties include publication bias, reluctance to implement such novel, technically-demanding, non-evidence-based practices (stem cell transplantation) and the unbalanced physical distribution of care providers. Currently, the Children' s Oncology Group (COG) is undertaking a promising international study (COG ARET 0321) that aims at defining the most appropriate treatment strategy for patients with extraocular retinoblastoma. 19 Results of this study are set to improve therapeutic outcomes for advanced retinoblastoma patients in developing countries. Overall, according to our review, treatment-related toxicity was as expected from a myeloablative high-dose chemotherapy regimen (grade IV myelosuppression and gastrointestinal toxicity) while treatment-associated mortality was rarely reported-only 1 of 77 patients (1.3%). The length of follow-up greatly varied between the included studies (from 2 to 103 months); however, this strategy achieved durable tumor control in approximately 60% of patients. Outcome appears to vary according to location of metastatic spread; patients with non-CNS metastases fair better than those with CNS disease. This is possibly secondary to the poor CNS penetration of conventional chemotherapeutic agents; only 47.1% of patients who received thiotepa subsequently developed CNS relapse. Overall, the outcome of patients with metastatic and relapsed retinoblastoma treated by high-dose chemotherapy followed by stem cell transplantation appears to be superior to historical controls treated by conventional chemotherapy. 8 Three studies addressed the role of high-dose chemotherapy followed by stem cell transplantation in patients with trilateral or bilateral advanced retinoblastoma. 10, 15, 16 Due to the small number of included cases (17 patients), accurate assessment of the safety of this therapeutic regimen was not possible; however, the reported morbidity/ mortality were within expectations (grade IV myelosuppression and 1 case of treatment- Table 3 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell transplant for tumor at the surgical margin of the optic nerve and/or extrascleral extension. related death). Nonethe ess, therapeutic outcome in these patients was superior to those presenting with metastatic disease (5 of the 7 evaluable patients [71.4%] were alive with no evidence of disease at the time of follow-up).
Two studies addressed the role of high-dose chemotherapy followed by stem cell transplantation in patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension. 2, 4 In these patients, treatment-related toxicity was within expectations while excellent outcome was achieved (6 of 7 patients were alive with no evidence of disease at the time of follow-up). Traditionally, these patients were offered external-beam radiotherapy; however, this is associated with significant side effects. Several studies have reported the occurrence of second malignancy following radiation therapy in retinoblastoma patients. [20] [21] [22] This is especially true for patients with bilateral retinoblastoma since the majority harbor inherited germline mutations which predispose to cancer. We attempted to assess the incidence of second malignancy in our review; however, and due to the short follow-up in most cases, most of the studies did not mention the occurrence of second malignancies in their respective patients. Furthermore, a significant proportion of the reviewed patients received radiotherapy in addition to high-dose chemotherapy (38 patients), and as such, we were unable to derive rigid conclusions on the incidence of second malignancy in retinoblastoma patients treated by highdose chemotherapy followed by stem cell transplantation. 2, 3, 6, 8, 10, 12, 13 In addition, radiation therapy has been linked with compromising the development and growth of orbital and facial bones during childhood. 23 As a consequence, parents are often reluctant to accept this potential side effect of external-beam radiation therapy. In these situations, high-dose chemotherapy followed by stem cell transplantation poses as an alternative approach to adjuvant radiation therapy.
In conclusion, this study represents the first detailed systematic review addressing the role of high-dose chemotherapy followed by stem cell transplantation in retinoblastoma patients. High-dose chemotherapy (using a platinum agent, an alkylating compound and etoposide) followed by stem cell transplantation is an effective and well-tolerated treatment strategy in patients with retinoblastoma. Durable tumor control is possible in patients with non-CNS metastases, with trilateral or bilateral advanced retinoblastoma, and in patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension. Patients with CNS metastases require thiotepa to improve tumor control.
